| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 50 | 2024 | 4958 | 2.160 |
Why?
|
| Spinal Neoplasms | 27 | 2017 | 670 | 1.680 |
Why?
|
| Radiosurgery | 12 | 2024 | 1383 | 1.170 |
Why?
|
| Glioblastoma | 18 | 2020 | 1776 | 0.910 |
Why?
|
| Neurosurgical Procedures | 14 | 2023 | 633 | 0.810 |
Why?
|
| Craniotomy | 11 | 2021 | 304 | 0.740 |
Why?
|
| Meningeal Neoplasms | 4 | 2023 | 473 | 0.740 |
Why?
|
| Glioma | 12 | 2021 | 1978 | 0.580 |
Why?
|
| Cerebral Ventricle Neoplasms | 4 | 2023 | 76 | 0.520 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2015 | 9 | 0.510 |
Why?
|
| Spinal Cord Compression | 6 | 2017 | 167 | 0.480 |
Why?
|
| Retrospective Studies | 74 | 2024 | 39890 | 0.450 |
Why?
|
| Middle Aged | 104 | 2024 | 90352 | 0.440 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2024 | 7895 | 0.440 |
Why?
|
| Central Nervous System | 1 | 2015 | 451 | 0.420 |
Why?
|
| Neoplasm Metastasis | 4 | 2020 | 5315 | 0.410 |
Why?
|
| Adult | 98 | 2024 | 82040 | 0.410 |
Why?
|
| Aged | 92 | 2024 | 73333 | 0.410 |
Why?
|
| Treatment Outcome | 60 | 2024 | 33737 | 0.400 |
Why?
|
| Aged, 80 and over | 52 | 2024 | 30998 | 0.370 |
Why?
|
| Postoperative Complications | 21 | 2017 | 5681 | 0.370 |
Why?
|
| Supratentorial Neoplasms | 2 | 2013 | 77 | 0.340 |
Why?
|
| Male | 99 | 2024 | 128315 | 0.340 |
Why?
|
| Skull Base Neoplasms | 7 | 2012 | 339 | 0.340 |
Why?
|
| Adolescent | 52 | 2022 | 32767 | 0.330 |
Why?
|
| Female | 102 | 2024 | 148940 | 0.330 |
Why?
|
| Thoracic Vertebrae | 3 | 2001 | 200 | 0.310 |
Why?
|
| Wakefulness | 4 | 2014 | 156 | 0.310 |
Why?
|
| Pia Mater | 1 | 2008 | 17 | 0.310 |
Why?
|
| Arachnoid | 1 | 2008 | 14 | 0.310 |
Why?
|
| Neoplasm Seeding | 1 | 2008 | 66 | 0.300 |
Why?
|
| Neutropenia | 5 | 2000 | 1006 | 0.300 |
Why?
|
| Humans | 129 | 2024 | 270740 | 0.290 |
Why?
|
| Laser Therapy | 3 | 2017 | 466 | 0.290 |
Why?
|
| Spine | 3 | 2015 | 312 | 0.280 |
Why?
|
| Sacrum | 4 | 2012 | 138 | 0.260 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 4831 | 0.260 |
Why?
|
| Catheters, Indwelling | 6 | 2013 | 383 | 0.250 |
Why?
|
| Cross Infection | 3 | 2001 | 550 | 0.250 |
Why?
|
| Monitoring, Intraoperative | 5 | 2014 | 264 | 0.250 |
Why?
|
| Young Adult | 28 | 2022 | 22251 | 0.250 |
Why?
|
| Drug Therapy, Combination | 5 | 2001 | 2345 | 0.240 |
Why?
|
| Stereotaxic Techniques | 4 | 2016 | 182 | 0.230 |
Why?
|
| Survival Rate | 22 | 2015 | 12541 | 0.230 |
Why?
|
| Neuronavigation | 2 | 2017 | 47 | 0.230 |
Why?
|
| Glioma, Subependymal | 1 | 2023 | 24 | 0.220 |
Why?
|
| Hyperthermia, Induced | 3 | 2017 | 511 | 0.220 |
Why?
|
| Incidence | 12 | 2015 | 5824 | 0.210 |
Why?
|
| Prognosis | 27 | 2015 | 22505 | 0.210 |
Why?
|
| Orthopedic Procedures | 3 | 2011 | 145 | 0.210 |
Why?
|
| Fourth Ventricle | 2 | 2023 | 49 | 0.200 |
Why?
|
| Multivariate Analysis | 13 | 2015 | 4328 | 0.200 |
Why?
|
| Pinealoma | 1 | 2022 | 50 | 0.200 |
Why?
|
| Karnofsky Performance Status | 7 | 2015 | 174 | 0.190 |
Why?
|
| Penicillanic Acid | 1 | 2001 | 22 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2020 | 6256 | 0.190 |
Why?
|
| Orbit Evisceration | 1 | 2021 | 47 | 0.190 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2021 | 31 | 0.190 |
Why?
|
| Lumbar Vertebrae | 4 | 2005 | 247 | 0.180 |
Why?
|
| Radiography | 7 | 2015 | 1986 | 0.180 |
Why?
|
| Survival Analysis | 20 | 2015 | 9292 | 0.180 |
Why?
|
| Sarcoma | 5 | 2014 | 1839 | 0.170 |
Why?
|
| Meningioma | 1 | 2023 | 308 | 0.170 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 339 | 0.170 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2019 | 33 | 0.170 |
Why?
|
| Pneumonia, Bacterial | 1 | 2001 | 135 | 0.170 |
Why?
|
| Pyramidal Tracts | 1 | 2019 | 58 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 4 | 2001 | 1757 | 0.170 |
Why?
|
| Opportunistic Infections | 1 | 2001 | 234 | 0.160 |
Why?
|
| Imipenem | 3 | 1998 | 28 | 0.160 |
Why?
|
| Cranial Fossa, Anterior | 2 | 2010 | 14 | 0.160 |
Why?
|
| Connectome | 1 | 2021 | 113 | 0.160 |
Why?
|
| Lung Neoplasms | 7 | 2014 | 12033 | 0.160 |
Why?
|
| Hospitals, University | 2 | 2020 | 218 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 7 | 2013 | 3187 | 0.160 |
Why?
|
| Catheterization, Central Venous | 5 | 2000 | 363 | 0.160 |
Why?
|
| Pseudomonas Infections | 1 | 2000 | 166 | 0.160 |
Why?
|
| Fungemia | 2 | 2000 | 119 | 0.160 |
Why?
|
| Prospective Studies | 18 | 2021 | 13414 | 0.150 |
Why?
|
| Child | 22 | 2017 | 30559 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2000 | 252 | 0.150 |
Why?
|
| Ganciclovir | 2 | 1999 | 194 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 2 | 2016 | 106 | 0.150 |
Why?
|
| SOXB1 Transcription Factors | 2 | 2015 | 119 | 0.150 |
Why?
|
| Follow-Up Studies | 18 | 2017 | 15218 | 0.150 |
Why?
|
| Risk Factors | 16 | 2015 | 17888 | 0.140 |
Why?
|
| Brain | 5 | 2016 | 4208 | 0.140 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2019 | 293 | 0.140 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 425 | 0.140 |
Why?
|
| Cohort Studies | 12 | 2021 | 9470 | 0.140 |
Why?
|
| Rifampin | 3 | 1998 | 218 | 0.140 |
Why?
|
| Nervous System Diseases | 4 | 2017 | 517 | 0.130 |
Why?
|
| Kidney Neoplasms | 4 | 2015 | 3108 | 0.130 |
Why?
|
| Methylmethacrylate | 2 | 2000 | 17 | 0.130 |
Why?
|
| Equipment Contamination | 3 | 1998 | 85 | 0.130 |
Why?
|
| Child, Preschool | 13 | 2015 | 17061 | 0.130 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2014 | 587 | 0.130 |
Why?
|
| Bone Screws | 2 | 2001 | 86 | 0.130 |
Why?
|
| Decompression, Surgical | 3 | 2016 | 144 | 0.130 |
Why?
|
| Osteosarcoma | 2 | 2014 | 950 | 0.130 |
Why?
|
| Skull Base | 3 | 2007 | 225 | 0.120 |
Why?
|
| Texas | 8 | 2020 | 6449 | 0.120 |
Why?
|
| Cognition | 1 | 2021 | 959 | 0.120 |
Why?
|
| Neoplasms | 7 | 2014 | 15927 | 0.120 |
Why?
|
| Cancer Care Facilities | 3 | 2015 | 907 | 0.120 |
Why?
|
| Candidiasis | 2 | 1997 | 278 | 0.120 |
Why?
|
| Deep Brain Stimulation | 1 | 2019 | 403 | 0.120 |
Why?
|
| Cervical Vertebrae | 2 | 2000 | 219 | 0.120 |
Why?
|
| Predictive Value of Tests | 7 | 2014 | 4960 | 0.110 |
Why?
|
| Cytomegalovirus Infections | 2 | 1999 | 495 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2014 | 112 | 0.110 |
Why?
|
| Temporal Lobe | 1 | 2015 | 191 | 0.110 |
Why?
|
| Glasgow Coma Scale | 1 | 2014 | 207 | 0.110 |
Why?
|
| Melanoma | 5 | 2024 | 5595 | 0.110 |
Why?
|
| Neurosurgery | 2 | 2015 | 117 | 0.110 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2014 | 106 | 0.110 |
Why?
|
| Bacterial Infections | 2 | 1998 | 510 | 0.110 |
Why?
|
| Thrombectomy | 1 | 2014 | 167 | 0.110 |
Why?
|
| Disability Evaluation | 1 | 2014 | 234 | 0.110 |
Why?
|
| Wounds, Gunshot | 1 | 2014 | 150 | 0.110 |
Why?
|
| Fluconazole | 3 | 2000 | 107 | 0.110 |
Why?
|
| Astrocytoma | 2 | 2013 | 326 | 0.110 |
Why?
|
| Oligodendroglioma | 2 | 2011 | 105 | 0.110 |
Why?
|
| Craniocerebral Trauma | 1 | 2014 | 154 | 0.110 |
Why?
|
| Phenytoin | 1 | 2013 | 81 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 2 | 2014 | 120 | 0.100 |
Why?
|
| Antiviral Agents | 3 | 1999 | 1253 | 0.100 |
Why?
|
| Breast Neoplasms | 6 | 2020 | 16215 | 0.100 |
Why?
|
| Antitubercular Agents | 1 | 2015 | 349 | 0.100 |
Why?
|
| Intraoperative Complications | 1 | 2014 | 288 | 0.100 |
Why?
|
| Mice, Nude | 4 | 2015 | 4329 | 0.100 |
Why?
|
| Eclampsia | 2 | 1997 | 35 | 0.100 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2015 | 2386 | 0.100 |
Why?
|
| Disease-Free Survival | 8 | 2023 | 10265 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2023 | 10400 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1145 | 0.090 |
Why?
|
| Catheterization | 1 | 2013 | 418 | 0.090 |
Why?
|
| Chordoma | 2 | 2006 | 170 | 0.090 |
Why?
|
| Registries | 4 | 2014 | 2211 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2011 | 77 | 0.090 |
Why?
|
| Back Pain | 2 | 2003 | 62 | 0.090 |
Why?
|
| Brain Stem Neoplasms | 1 | 2011 | 100 | 0.090 |
Why?
|
| Cerebrum | 1 | 2010 | 40 | 0.090 |
Why?
|
| Extracellular Space | 1 | 2010 | 136 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2013 | 274 | 0.090 |
Why?
|
| Bone Substitutes | 1 | 2000 | 18 | 0.090 |
Why?
|
| Third Ventricle | 1 | 2010 | 38 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2014 | 7381 | 0.090 |
Why?
|
| Logistic Models | 8 | 2014 | 3444 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 2015 | 762 | 0.090 |
Why?
|
| Pain Measurement | 5 | 2015 | 1016 | 0.090 |
Why?
|
| Cerebral Ventricles | 1 | 2010 | 106 | 0.090 |
Why?
|
| Corpus Callosum | 1 | 2010 | 127 | 0.080 |
Why?
|
| Anticonvulsants | 1 | 2013 | 430 | 0.080 |
Why?
|
| Seizures | 2 | 2013 | 1001 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2011 | 199 | 0.080 |
Why?
|
| Amphotericin B | 2 | 2000 | 298 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2010 | 131 | 0.080 |
Why?
|
| Motor Cortex | 1 | 2010 | 126 | 0.080 |
Why?
|
| Cerebral Cortex | 2 | 2013 | 623 | 0.080 |
Why?
|
| Radiotherapy | 3 | 2010 | 1857 | 0.080 |
Why?
|
| Clinical Clerkship | 1 | 2010 | 107 | 0.080 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2013 | 522 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 242 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2015 | 1604 | 0.080 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 5101 | 0.080 |
Why?
|
| Mycobacterium fortuitum | 1 | 1998 | 2 | 0.080 |
Why?
|
| Mycobacterium chelonae | 1 | 1998 | 7 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2013 | 447 | 0.080 |
Why?
|
| Skull | 1 | 2010 | 251 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 602 | 0.080 |
Why?
|
| Cilastatin | 1 | 1998 | 6 | 0.080 |
Why?
|
| Orthopedic Fixation Devices | 2 | 2003 | 19 | 0.080 |
Why?
|
| Hemifacial Spasm | 1 | 2008 | 22 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2014 | 931 | 0.080 |
Why?
|
| Thienamycins | 1 | 1998 | 23 | 0.080 |
Why?
|
| Infection Control | 2 | 1998 | 278 | 0.080 |
Why?
|
| Thromboplastin | 1 | 2008 | 33 | 0.080 |
Why?
|
| Wound Infection | 1 | 1999 | 66 | 0.080 |
Why?
|
| Glutamic Acid | 1 | 2010 | 335 | 0.080 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1998 | 175 | 0.080 |
Why?
|
| Novobiocin | 1 | 1998 | 7 | 0.080 |
Why?
|
| Nursing Staff, Hospital | 1 | 1999 | 74 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2010 | 402 | 0.080 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2008 | 50 | 0.080 |
Why?
|
| Infant | 5 | 2014 | 13999 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 605 | 0.070 |
Why?
|
| Immunocompromised Host | 2 | 2003 | 719 | 0.070 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 1998 | 86 | 0.070 |
Why?
|
| Pons | 1 | 2008 | 54 | 0.070 |
Why?
|
| Facial Bones | 1 | 2007 | 46 | 0.070 |
Why?
|
| Antibiotics, Antitubercular | 2 | 1998 | 43 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2015 | 2170 | 0.070 |
Why?
|
| ErbB Receptors | 2 | 2007 | 2375 | 0.070 |
Why?
|
| Vancomycin | 2 | 1996 | 292 | 0.070 |
Why?
|
| p21-Activated Kinases | 1 | 2007 | 131 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2014 | 917 | 0.070 |
Why?
|
| Protease Inhibitors | 1 | 1998 | 206 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2024 | 1430 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2001 | 3046 | 0.070 |
Why?
|
| Electric Stimulation | 3 | 2014 | 453 | 0.070 |
Why?
|
| Cefoperazone | 1 | 1996 | 7 | 0.070 |
Why?
|
| Sulbactam | 1 | 1996 | 10 | 0.070 |
Why?
|
| Language | 1 | 2009 | 326 | 0.070 |
Why?
|
| Chondrosarcoma | 1 | 1999 | 213 | 0.070 |
Why?
|
| Fever | 2 | 1998 | 521 | 0.070 |
Why?
|
| Antineoplastic Agents | 6 | 2010 | 14617 | 0.070 |
Why?
|
| Combined Modality Therapy | 8 | 2015 | 9039 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 953 | 0.070 |
Why?
|
| Virus Diseases | 1 | 2000 | 393 | 0.070 |
Why?
|
| Microsurgery | 1 | 2008 | 235 | 0.070 |
Why?
|
| Confidence Intervals | 4 | 2010 | 749 | 0.070 |
Why?
|
| Minocycline | 2 | 1998 | 189 | 0.070 |
Why?
|
| Walking | 3 | 2009 | 216 | 0.070 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2023 | 2271 | 0.070 |
Why?
|
| Candida | 1 | 1997 | 171 | 0.060 |
Why?
|
| Aztreonam | 2 | 2001 | 15 | 0.060 |
Why?
|
| Age Distribution | 4 | 2009 | 727 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2006 | 273 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2006 | 286 | 0.060 |
Why?
|
| Chitinase-3-Like Protein 1 | 3 | 2012 | 17 | 0.060 |
Why?
|
| Bone Plates | 2 | 2000 | 50 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2015 | 2651 | 0.060 |
Why?
|
| Memory | 2 | 2021 | 445 | 0.060 |
Why?
|
| Microglia | 1 | 2006 | 181 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2005 | 136 | 0.060 |
Why?
|
| Necrosis | 2 | 2008 | 595 | 0.060 |
Why?
|
| Palliative Care | 2 | 2015 | 2178 | 0.060 |
Why?
|
| Lectins | 3 | 2012 | 148 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2011 | 1542 | 0.060 |
Why?
|
| Antifungal Agents | 1 | 2000 | 880 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2015 | 1894 | 0.060 |
Why?
|
| Brain Injuries | 1 | 2010 | 776 | 0.060 |
Why?
|
| Adipokines | 3 | 2012 | 97 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 1998 | 889 | 0.060 |
Why?
|
| Orbit | 2 | 2002 | 209 | 0.060 |
Why?
|
| Postoperative Period | 3 | 2009 | 666 | 0.060 |
Why?
|
| Facial Neoplasms | 1 | 2004 | 77 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1718 | 0.060 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 1456 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 1997 | 496 | 0.060 |
Why?
|
| Time Factors | 8 | 2014 | 13006 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 669 | 0.060 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 2003 | 7 | 0.050 |
Why?
|
| Patient Care Team | 1 | 1999 | 823 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2009 | 1312 | 0.050 |
Why?
|
| Respirovirus Infections | 1 | 2003 | 30 | 0.050 |
Why?
|
| Atlanto-Axial Joint | 1 | 2003 | 26 | 0.050 |
Why?
|
| Disease Progression | 6 | 2015 | 6867 | 0.050 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 1997 | 444 | 0.050 |
Why?
|
| Kyphosis | 2 | 2003 | 45 | 0.050 |
Why?
|
| Cerebellar Neoplasms | 1 | 2008 | 477 | 0.050 |
Why?
|
| Awards and Prizes | 1 | 2004 | 86 | 0.050 |
Why?
|
| Patient Selection | 2 | 2014 | 2025 | 0.050 |
Why?
|
| Leukemia | 2 | 2003 | 1719 | 0.050 |
Why?
|
| Lung Diseases | 1 | 1998 | 755 | 0.050 |
Why?
|
| Bone Cements | 2 | 2003 | 50 | 0.050 |
Why?
|
| Recovery of Function | 3 | 2015 | 681 | 0.050 |
Why?
|
| Carcinoid Tumor | 1 | 2004 | 282 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2024 | 2033 | 0.050 |
Why?
|
| MicroRNAs | 1 | 2015 | 2887 | 0.050 |
Why?
|
| Intestinal Neoplasms | 1 | 2004 | 205 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2003 | 111 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2007 | 1138 | 0.050 |
Why?
|
| Transplantation Conditioning | 1 | 2001 | 2374 | 0.050 |
Why?
|
| Sex Distribution | 3 | 2009 | 497 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 1388 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2022 | 45 | 0.050 |
Why?
|
| Hematologic Neoplasms | 2 | 2000 | 1956 | 0.050 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2002 | 155 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2009 | 5574 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2003 | 138 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2008 | 1563 | 0.050 |
Why?
|
| Piperacillin | 1 | 2001 | 30 | 0.050 |
Why?
|
| Amikacin | 1 | 2001 | 37 | 0.050 |
Why?
|
| Clindamycin | 1 | 2001 | 53 | 0.050 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2004 | 327 | 0.050 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2000 | 1076 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2004 | 522 | 0.050 |
Why?
|
| Stroke | 1 | 2009 | 1049 | 0.050 |
Why?
|
| Risk | 3 | 2016 | 1939 | 0.050 |
Why?
|
| Biomarkers, Tumor | 3 | 2015 | 10708 | 0.050 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2004 | 442 | 0.040 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2004 | 444 | 0.040 |
Why?
|
| Postoperative Care | 2 | 2017 | 728 | 0.040 |
Why?
|
| Carcinoma, Papillary | 1 | 2004 | 566 | 0.040 |
Why?
|
| Ophthalmologic Surgical Procedures | 1 | 2001 | 141 | 0.040 |
Why?
|
| Lactams | 1 | 2000 | 27 | 0.040 |
Why?
|
| Nervous System | 2 | 2001 | 183 | 0.040 |
Why?
|
| Ependymoma | 1 | 2002 | 264 | 0.040 |
Why?
|
| Executive Function | 1 | 2021 | 146 | 0.040 |
Why?
|
| Macrophages | 1 | 2006 | 1350 | 0.040 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2004 | 499 | 0.040 |
Why?
|
| Methylmethacrylates | 1 | 1998 | 22 | 0.040 |
Why?
|
| Orbital Neoplasms | 1 | 2001 | 234 | 0.040 |
Why?
|
| Internship and Residency | 1 | 2010 | 1452 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2069 | 0.040 |
Why?
|
| Brain Mapping | 2 | 2014 | 624 | 0.040 |
Why?
|
| Pulmonary Atelectasis | 1 | 1998 | 51 | 0.040 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 7914 | 0.040 |
Why?
|
| Neoplasm, Residual | 2 | 2015 | 1754 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2015 | 9042 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 6177 | 0.040 |
Why?
|
| Sepsis | 2 | 1999 | 686 | 0.040 |
Why?
|
| Nerve Net | 1 | 2021 | 272 | 0.040 |
Why?
|
| Cranial Irradiation | 3 | 2004 | 322 | 0.040 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2001 | 3156 | 0.040 |
Why?
|
| Muscle Weakness | 1 | 1998 | 111 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2010 | 2311 | 0.040 |
Why?
|
| Cranial Nerve Injuries | 1 | 2017 | 9 | 0.040 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 1823 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2012 | 1553 | 0.040 |
Why?
|
| Tocolytic Agents | 1 | 1997 | 13 | 0.040 |
Why?
|
| Ventriculostomy | 1 | 2017 | 43 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 14849 | 0.040 |
Why?
|
| Magnesium Sulfate | 1 | 1997 | 56 | 0.040 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 45 | 0.030 |
Why?
|
| Pain, Intractable | 1 | 1998 | 180 | 0.030 |
Why?
|
| Speech Disorders | 1 | 2017 | 85 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2017 | 89 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2004 | 801 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2017 | 223 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2010 | 4000 | 0.030 |
Why?
|
| Case-Control Studies | 4 | 2005 | 6224 | 0.030 |
Why?
|
| Pain, Postoperative | 2 | 2015 | 662 | 0.030 |
Why?
|
| Anesthesia, General | 1 | 2017 | 222 | 0.030 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2001 | 7044 | 0.030 |
Why?
|
| Patient Positioning | 1 | 2017 | 196 | 0.030 |
Why?
|
| Immunohistochemistry | 4 | 2008 | 7655 | 0.030 |
Why?
|
| Risk Assessment | 3 | 2015 | 6764 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 1998 | 342 | 0.030 |
Why?
|
| Adie Syndrome | 1 | 2014 | 4 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2022 | 1690 | 0.030 |
Why?
|
| Acute Disease | 1 | 2000 | 2493 | 0.030 |
Why?
|
| Photomicrography | 1 | 2014 | 23 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 1997 | 237 | 0.030 |
Why?
|
| Probability | 2 | 2009 | 886 | 0.030 |
Why?
|
| Immunosuppressive Agents | 2 | 2001 | 1432 | 0.030 |
Why?
|
| Ohio | 1 | 2014 | 117 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2014 | 76 | 0.030 |
Why?
|
| Algorithms | 2 | 2020 | 3891 | 0.030 |
Why?
|
| Luminescent Measurements | 1 | 2014 | 158 | 0.030 |
Why?
|
| Vascular Patency | 1 | 2014 | 189 | 0.030 |
Why?
|
| Biopsy | 1 | 2001 | 3484 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 346 | 0.030 |
Why?
|
| Mutation | 1 | 2013 | 15912 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 2004 | 3077 | 0.030 |
Why?
|
| Meningitis | 1 | 2013 | 126 | 0.030 |
Why?
|
| Glycoproteins | 2 | 2007 | 779 | 0.030 |
Why?
|
| Memory Disorders | 1 | 2015 | 287 | 0.030 |
Why?
|
| Intracranial Hypertension | 1 | 2014 | 126 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2009 | 2315 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 5162 | 0.030 |
Why?
|
| Carcinoma | 1 | 2003 | 2610 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 5866 | 0.020 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2014 | 368 | 0.020 |
Why?
|
| Heterografts | 1 | 2014 | 738 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2014 | 7783 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 909 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2020 | 1465 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2005 | 5002 | 0.020 |
Why?
|
| Quality of Life | 2 | 2016 | 4761 | 0.020 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2001 | 88 | 0.020 |
Why?
|
| Thiotepa | 1 | 2001 | 132 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2001 | 7265 | 0.020 |
Why?
|
| Spheroids, Cellular | 1 | 2012 | 220 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2014 | 562 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2353 | 0.020 |
Why?
|
| Mice | 4 | 2015 | 35600 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2003 | 2328 | 0.020 |
Why?
|
| Motor Skills Disorders | 1 | 2010 | 18 | 0.020 |
Why?
|
| Animals | 5 | 2015 | 61956 | 0.020 |
Why?
|
| Microdialysis | 1 | 2010 | 70 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2005 | 5438 | 0.020 |
Why?
|
| Evoked Potentials, Motor | 1 | 2010 | 60 | 0.020 |
Why?
|
| Chickens | 1 | 2011 | 783 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2008 | 1580 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2000 | 243 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2015 | 1042 | 0.020 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 3240 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 4372 | 0.020 |
Why?
|
| Pain | 2 | 2005 | 1694 | 0.020 |
Why?
|
| Embolization, Therapeutic | 1 | 2015 | 605 | 0.020 |
Why?
|
| Spinal Canal | 1 | 2009 | 15 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2000 | 141 | 0.020 |
Why?
|
| Candida albicans | 1 | 2000 | 186 | 0.020 |
Why?
|
| Asepsis | 1 | 1999 | 5 | 0.020 |
Why?
|
| Intracranial Pressure | 1 | 2010 | 197 | 0.020 |
Why?
|
| Reoperation | 2 | 2005 | 1392 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1076 | 0.020 |
Why?
|
| Phosphorylation | 2 | 2007 | 4942 | 0.020 |
Why?
|
| Morbidity | 1 | 2010 | 400 | 0.020 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 31 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 4048 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2012 | 7238 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2000 | 150 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 262 | 0.020 |
Why?
|
| Narcotics | 1 | 2009 | 127 | 0.020 |
Why?
|
| Shock, Septic | 1 | 2000 | 188 | 0.020 |
Why?
|
| Facial Nerve | 1 | 2008 | 58 | 0.020 |
Why?
|
| Bandages | 1 | 1999 | 75 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2008 | 138 | 0.020 |
Why?
|
| Colony Count, Microbial | 1 | 1998 | 159 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 1998 | 1468 | 0.020 |
Why?
|
| Lymphocyte Depletion | 1 | 1999 | 316 | 0.020 |
Why?
|
| Urinary Incontinence | 1 | 2009 | 148 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1060 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 2007 | 0.020 |
Why?
|
| Stents | 1 | 2014 | 999 | 0.020 |
Why?
|
| Mentors | 1 | 2010 | 210 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2008 | 177 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 4795 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 608 | 0.020 |
Why?
|
| Protective Devices | 1 | 1997 | 19 | 0.020 |
Why?
|
| Patient Isolation | 1 | 1997 | 25 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 1388 | 0.020 |
Why?
|
| Hand Disinfection | 1 | 1997 | 23 | 0.020 |
Why?
|
| Visitors to Patients | 1 | 1997 | 14 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 5694 | 0.020 |
Why?
|
| Steroids | 1 | 2009 | 372 | 0.020 |
Why?
|
| Medical Records | 1 | 1999 | 442 | 0.020 |
Why?
|
| Busulfan | 1 | 2001 | 794 | 0.020 |
Why?
|
| Inservice Training | 1 | 1997 | 74 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1133 | 0.020 |
Why?
|
| Faculty, Medical | 1 | 2010 | 313 | 0.020 |
Why?
|
| Antibody-Producing Cells | 1 | 2006 | 20 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2000 | 681 | 0.020 |
Why?
|
| Chemoprevention | 1 | 1998 | 251 | 0.020 |
Why?
|
| Ribavirin | 1 | 1997 | 177 | 0.020 |
Why?
|
| Graft Survival | 1 | 2000 | 1083 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 453 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2011 | 2454 | 0.020 |
Why?
|
| Vomiting | 1 | 1998 | 361 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 1998 | 153 | 0.020 |
Why?
|
| Oxygen | 1 | 2010 | 791 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2008 | 531 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 135 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2014 | 1207 | 0.020 |
Why?
|
| Gram-Positive Bacteria | 1 | 1996 | 68 | 0.020 |
Why?
|
| Demography | 1 | 2007 | 433 | 0.020 |
Why?
|
| Nausea | 1 | 1998 | 539 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1996 | 107 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 702 | 0.020 |
Why?
|
| Parity | 1 | 1995 | 136 | 0.020 |
Why?
|
| CD146 Antigen | 1 | 2005 | 56 | 0.020 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2005 | 53 | 0.020 |
Why?
|
| Maternal Age | 1 | 1995 | 147 | 0.020 |
Why?
|
| Transcription Factor AP-2 | 1 | 2005 | 78 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 1995 | 241 | 0.020 |
Why?
|
| Students, Medical | 1 | 2010 | 423 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 1997 | 520 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 5457 | 0.020 |
Why?
|
| Jejunal Neoplasms | 1 | 2004 | 32 | 0.010 |
Why?
|
| Abortion, Induced | 1 | 1995 | 94 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1996 | 735 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2001 | 1567 | 0.010 |
Why?
|
| Ileal Neoplasms | 1 | 2004 | 49 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2012 | 5759 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 1995 | 107 | 0.010 |
Why?
|
| Cell Movement | 1 | 2012 | 2472 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 2057 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 399 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 258 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1998 | 672 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 1571 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 1608 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2001 | 3245 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1998 | 1179 | 0.010 |
Why?
|
| Duodenal Neoplasms | 1 | 2004 | 138 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 537 | 0.010 |
Why?
|
| Cell Line | 1 | 2011 | 5338 | 0.010 |
Why?
|
| Transfection | 1 | 2008 | 3117 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 4223 | 0.010 |
Why?
|
| Sensation Disorders | 1 | 2002 | 35 | 0.010 |
Why?
|
| Gene Expression | 1 | 2011 | 3640 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 484 | 0.010 |
Why?
|
| Urinary Bladder | 1 | 2005 | 593 | 0.010 |
Why?
|
| Fractures, Spontaneous | 1 | 2003 | 87 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 902 | 0.010 |
Why?
|
| Bacteremia | 1 | 1998 | 721 | 0.010 |
Why?
|
| Body Height | 1 | 2003 | 234 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2007 | 2196 | 0.010 |
Why?
|
| Neutrophils | 1 | 1996 | 873 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2011 | 2457 | 0.010 |
Why?
|
| Urinary Tract Infections | 1 | 1995 | 345 | 0.010 |
Why?
|
| Intestines | 1 | 2005 | 736 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 984 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 1379 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 5056 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5149 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 1418 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2011 | 7100 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2006 | 1563 | 0.010 |
Why?
|
| Oncology Service, Hospital | 1 | 1999 | 49 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 2471 | 0.010 |
Why?
|
| Pregnancy | 2 | 1997 | 8130 | 0.010 |
Why?
|
| Drug Stability | 1 | 1998 | 106 | 0.010 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 1997 | 133 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1998 | 243 | 0.010 |
Why?
|
| Apoptosis | 1 | 2012 | 7757 | 0.010 |
Why?
|
| Lung | 1 | 1998 | 3298 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 452 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 2394 | 0.010 |
Why?
|
| Bias | 1 | 1997 | 216 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2115 | 0.010 |
Why?
|
| Cause of Death | 1 | 1999 | 789 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1997 | 607 | 0.010 |
Why?
|
| DNA, Viral | 1 | 1997 | 756 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 3844 | 0.010 |
Why?
|
| Recurrence | 1 | 2003 | 4878 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1997 | 964 | 0.010 |
Why?
|
| Obesity | 1 | 1995 | 2904 | 0.010 |
Why?
|
| United States | 1 | 2010 | 15861 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1997 | 2580 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 14012 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1997 | 2650 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 5593 | 0.000 |
Why?
|
| Signal Transduction | 1 | 2006 | 12103 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1998 | 16689 | 0.000 |
Why?
|